Acesso livre
Acesso livre

M-A | Colchicina não reduz a gravidade da COVID-19 nem evita o risco de morte.

23 Nov, 2021 | 15:53h

Comunicado de imprensa: Gout drug colchicine doesn’t lessen COVID-19 severity or stave off risk of death – BMJ

Estudo original: Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials – RMD Open

Conteúdos relacionados:

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

Mantenha-se atualizado em sua especialidade


Escolha quantas especialidades quiser.